Walter Kolch
Systems Biology Ireland, University College Dublin, Dublin, Ireland
Walter Kolch is Director of Systems Biology Ireland (https://www.ucd.ie/sbi/) and the Precision Oncology Ireland Consortium (https://www.precisiononcology.ie/). Trained as an MD he worked in experimental clinical research, pharmaceutical industry, and basic biological research. Before moving to Dublin in 2009 he held a Chair for Molecular Cell Biology at the University of Glasgow and was a Senior Group Leader at the Beatson Institute for Cancer Research in Glasgow, Scotland. He is best known for his work in oncogene signal transduction, proteomics, systems biology, and precision medicine. He is ranked No 3 in world in precision oncology by citations. He has made salient contributions to elucidating the function of the RAS-RAF pathway, and more recently to understand network wide effects of oncogenes. His current research interest focuses on understanding molecular mechanisms of malignant transformation, network mediated drug resistance in cancer, and the construction of Digital Twins for personalized cancer diagnosis and therapy. He serves on several editorial boards and scientific advisory boards and is a Fellow of the Royal Society of Edinburgh and a Member of the Royal Irish Academy.
Walter Kolch is Director of Systems Biology Ireland (https://www.ucd.ie/sbi/) and the Precision Oncology Ireland Consortium (https://www.precisiononcology.ie/). Trained as an MD he worked in experimental clinical research, pharmaceutical industry, and basic biological research. Before moving to Dublin in 2009 he held a Chair for Molecular Cell Biology at the University of Glasgow and was a Senior Group Leader at the Beatson Institute for Cancer Research in Glasgow, Scotland. He is best known for his work in oncogene signal transduction, proteomics, systems biology, and precision medicine. He is ranked No 3 in world in precision oncology by citations. He has made salient contributions to elucidating the function of the RAS-RAF pathway, and more recently to understand network wide effects of oncogenes. His current research interest focuses on understanding molecular mechanisms of malignant transformation, network mediated drug resistance in cancer, and the construction of Digital Twins for personalized cancer diagnosis and therapy. He serves on several editorial boards and scientific advisory boards and is a Fellow of the Royal Society of Edinburgh and a Member of the Royal Irish Academy.
